Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ALC-2216
- Development stage
- Preclinical
- Lead developer
- Korea Arlico Pharm
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
ALC-2216 is a generic drug candidate developed by **Korea Arlico Pharm**, a South Korean pharmaceutical company. The drug is currently in the development pipeline and is intended for the treatment of **digestive system** disorders. As a generic product, ALC-2216 is being developed to be bioequivalent to an existing reference drug, providing a cost-effective alternative once the original product's patent protection expires. While the specific active pharmaceutical ingredient (API) and its exact mechanism of action have not been publicly disclosed by the sponsor, it is classified as a small molecule generic within the company's gastrointestinal portfolio.
Beyond the preview
Go deeper on ALC-2216.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ALC-2216.